ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$12.76
arrow_downward
-1.81%(-0.23) 1D
$12.61
arrow_downward
-1.21% (-0.16)bedtimeAfter hours
Closed: Oct 7, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARCT...
Open
$12.71
High
$13.40
Low
$12.59
Mkt. cap
362.82M
Avg. vol.
1.03M
Volume
517.81K
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
Open
$12.71
High
$13.40
Low
$12.59
Mkt. cap
362.82M
Avg. vol.
1.03M
Volume
517.81K
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
News stories
From web sources and news partners
Stock Titan
·
12 hours ago
A trust joins the reporting parties for 1.68M Arcturus Therapeutics (ARCT) shares.
Stock Traders Daily
·
1 day ago
Discipline and Rules-Based Execution in ARCT Response
https://www.dars.gov.et/
·
2 weeks ago
Arcturus Therapeutics (ARCT) Slips 2.11% to $14.38 as Shares Drift Toward Range Support - Investment Factor
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc